The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | GIST: an update from ESMO 2020
Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK, gives an update on gastrointestinal stromal tumor (GIST) studies. Firstly, Dr Jones discusses a Phase III trial INVICTUS (NCT03353753) which investigates the use of ripretinib vs placebo in patients who have received treatment with prior anticancer therapies. Secondly, Dr Jones discusses a Phase I trial (NCT02571036), this trial is a dose-escalation study which investigates the safety and tolerability of ripretinib in patients with advanced malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
